je.st
news
Tag: sanofi
Regeneron Pharmaceuticals major shareholder Sanofi Acquires 147,209 Shares
2015-09-27 09:48:03| Apparel - Topix.net
Regeneron Pharmaceuticals major shareholder Sanofi bought 147,209 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, September 23rd. The shares were bought at an average cost of $534.67 per share, with a total value of $78,708,236.03.
Tags: major
shares
shareholder
pharmaceuticals
Sanofi reports higher profit in 2nd quarter
2015-07-30 09:53:03| Biotech - Topix.net
" Drugmaker Sanofi has reported a sharp rise in profits in the second quarter as higher sales from its Cambridge, Mass.-based biotech unit Genzyme helped offset by cuts in the price of the company's diabetes treatment Lantus in the U.S. Sanofi reported Tuesday net profit of 1.3 billion euros from April to June, up from 777 million euros a year earlier. Paris-based Sanofi, whose new CEO Olivier Brandicourt took over in April, said it's on track to hit earnings targets set out earlier this year, with flat to slightly higher earnings per share.
Tags: reports
higher
2nd
profit
Sanofi Cholesterol Drug, GSK Malaria Shot May Get EU Okay Friday
2015-07-21 16:29:02| Biotech - Topix.net
Sanofi and Regeneron's new cholesterol drug Praluent could be recommended for approval in Europe as early as this week, along with the world's first malaria vaccine from GlaxoSmithKline.
Former Sanofi CEO reinvents himself, staying in Boston
2015-06-23 19:43:19| Biotech - Topix.net
Viehbacher, the former chief executive of France's largest drug maker, will run Swiss billionaire Ernesto Bertarelli's U.S. based Gurnet Point Capital fund, according to a statement. He has also joined the board of the technology transfer company PureTech Health Plc, which raised $171 million in an initial public offering on the London Stock Exchange this month.
Fired Sanofi chief joins Boston's PureTech
2015-02-28 00:10:11| Biotech - Topix.net
Christopher A. Viehbacher, the former Sanofi SA chief executive who engineered its $20.1 billion buyout of Cambridge's Genzyme Corp. in 2011, has been named a senior partner and board member at PureTech, a Boston research and development firm that incubates and bankrolls biotech startups. The move suggests that Viehbacher, who was fired by French drug maker Sanofi last year after he moved his primary residence from Paris to Massachusetts, plans to keep a high profile in the Boston area, which has emerged as a global hub for the life sciences.
Tags: chief
fired
joins
sanofi
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] next »